Analyst Ratings For NASDAQ:AIMT – Aimmune Therapeutics (NASDAQ:AIMT)
Today, Cantor Fitzgerald reiterated its Buy rating on NASDAQ:AIMT – Aimmune Therapeutics (NASDAQ:AIMT) with a price target of $64.00.
Some recent analyst ratings include
- 5/9/2018-Cantor Fitzgerald Reiterated Rating of Buy.
- 3/6/2018-Wedbush Reiterated Rating of Outperform.
Recent Insider Trading Activity For NASDAQ:AIMT – Aimmune Therapeutics (NASDAQ:AIMT)
NASDAQ:AIMT – Aimmune Therapeutics (NASDAQ:AIMT) has insider ownership of 14.70% and institutional ownership of 65.25%.
- On 3/5/2018 Douglas T Sheehy, Insider, sold 3,523 with an average share price of $36.52 per share and the total transaction amounting to $128,659.96.
- On 3/1/2018 Mary M Rozenman, Insider, sold 1,807 with an average share price of $33.10 per share and the total transaction amounting to $59,811.70.
- On 2/26/2018 Eric Bjerkholt, CFO, bought 3,125 with an average share price of $32.00 per share and the total transaction amounting to $100,000.00.
- On 2/26/2018 Kathryn E Falberg, Director, bought 30,000 with an average share price of $32.00 per share and the total transaction amounting to $960,000.00.
- On 2/22/2018 Bakker Juliet Tammenoms, Major Shareholder, bought 9,375 with an average share price of $32.00 per share and the total transaction amounting to $300,000.00.
- On 2/22/2018 Patrick G Enright, Director, bought 15,593 with an average share price of $32.00 per share and the total transaction amounting to $498,976.00.
- On 2/5/2018 Douglas T Sheehy, Insider, sold 1,648 with an average share price of $35.87 per share and the total transaction amounting to $59,113.76.
Recent Trading Activity for NASDAQ:AIMT – Aimmune Therapeutics (NASDAQ:AIMT)
Shares of NASDAQ:AIMT – Aimmune Therapeutics closed the previous trading session at 29.92 down -1.07 3.45% with 30.75 shares trading hands.